Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab + gemcitabine + anlotinib in first-line metastatic nasopharyngeal carcinoma
CTR20210230Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab in nasopharyngeal carcinoma (NPC), sponsored by Akeso, Inc.. Started Feb 2021; status: terminated.
02
Drugs
penpulimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20210230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210230.